Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by pabalooon Sep 29, 2020 11:57am
86 Views
Post# 31635232

RE:RE:RE:RE:distribution deals next week?

RE:RE:RE:RE:distribution deals next week?Actually it's Cipher who is better off without the deal. On the Activis front they have not even submitted there generic version yet so approval may be a year away not sure why but low market share may and cost must have scared them from launching. Definitely a bonus for Cipher with no competition they should be able to increase market share with the LD version. The analysts had halved revenue in the coming quarters because of the generic version and completion but will probably revise and that means Cipher should enjoy a .10 earnings per quarter until Trulance and later next year Trevyent which could add another .05 cents. All this while cash is piling into the bank. Looking at Bausch for the take out soon.
Bullboard Posts